TLR8-AGONIST

European patent · EP3854794 · In force

Register entry

Publication number
EP3854794
Application number
EP19862693
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 19, 2019
Published
Jul 28, 2021
Granted
Nov 27, 2024
Protection ends at the latest
Sep 18, 2039
Next annual fee due
Sep 30, 2027
IPC classes
C07D 471/04 (2006.01)
C07D 249/08 (2006.01)
A61K 31/519 (2006.01)
A61P 31/12 (2006.01)
Priority
CN 201811094969 19.09.2018
PCT application
PCT/CN2019/106687 19.09.2019
PCT publication
WO2020/057604 26.03.2020
Filing language
Chinese
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. Oct 8, 2025

    Change

    Published in Swissreg on 08.10.2025

  3. Oct 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.09.2025 → 30.09.2026

    Published in Swissreg on 01.10.2025

  4. Nov 29, 2024

    Agent entered

    Representative
    VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 29.11.2024

  5. Nov 27, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 27.11.2024

Parties

Holder

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

No. 369 Yuzhou South Road, Lianyungang, Jiangsu 222062, CN

Agent

VALIPAT c/o BOVARD LTD

Optingenstrasse 16, 3013 Bern

Inventor

CAI, Zhe

Shanghai 200131, CN

SUN, Fei

Shanghai 200131, CN

DING, Charles Z.

Shanghai 200131, CN

CHEN, Shuhui

Shanghai 200131, CN

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.